Anti-CYP1A2 Antibody (9D8) is a Rabbit antibody targeting CYP1A2. Anti-CYP1A2 Antibody (9D8) can be used in WB,ICC/IF,FCM.

IgG

9D8

Human

1. 25 μg total protein per lane of various lysates (see on figure) probed with CYP1A2 monoclonal antibody, unconjugated (TMAB-04871) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r. T. for 60 min.
2. 4% Paraformaldehyde-fixed Hela (H) cell; Triton X-100 at r. T. for 20 min; Antibody incubation with (CYP1A2) monoclonal Antibody, unconjugated (TMAB-04871) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green) at 37°C for 90 min, DAPI (blue) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.

WB: 1:500-2000; ICC/IF: 1:50-200; FCM: 1:50-100

Monoclonal

A synthesized peptide: human Cytochrome P450 1A2

Human

CYP1A2

Cytochrome P450 1A2

Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.